Leerink Partners maintains Tenet Healthcare at Outperform, raises price target to $342 from $309
Leerink Partners kept its Outperform rating on Tenet Healthcare and raised its price target to $342 from $309, citing a 25.2% upside from the Oct 30 close of $273.25. Recent analyst price targets for the company range from $304 to $321.
How this was made

The 30-second read
Why it matters
The price target increase signals confidence in Tenet's near‑term performance, potentially prompting short‑term buying.
Market read
Analyst target raise provides a fresh catalyst for THC, offering a modest trading edge.
What to watch
Potential regulatory or reimbursement risks not addressed in the note.
Background
Tenet Healthcare (THC) is a U.S. hospital operator; analyst upgrades can move its stock.
Ticker impact
Leerink Partners raised Tenet Healthcare's price target to $342 from $309.
likely upward pressure as investors price in the higher target
The new target implies a 25% upside from current price, which may attract buying interest.
Market effects
May lift sentiment in the healthcare services sector.
Limited to U.S. markets where Tenet trades.
Low
Counterpoint
Target raise could be premature if earnings miss expectations.
Key entities
- companyTenet Healthcare
U.S. hospital operator
- analystLeerink Partners
Equity research firm issuing the target raise


